PARP1 and ovarian carcinoma: The most advanced case is the PARP-1 inhibitors, on their own or in combination with DNA-damaging chemotherapeutics, which are in phase-II clinical trials with breast/ovarian cancer patients having BRCA1/BRCA2 null tumours.